Table 2.
Baseline assessment | Lovastatin | Placebo | ||||
---|---|---|---|---|---|---|
Mean (S.E.) | Range | Mean (S.E.) | Range | Mean (S.E.) | Range | |
HERMES | ||||||
Fit Error (%) | 6.30 (0.45) | 3.31–8.15 | 6.77 (0.42) | 4.13–8.91 | 7.36 (0.55) | 4.86–9.68 |
FWHM (Hz) | 10.43 (0.67) | 8.97–15.50 | 10.00 (0.46) | 7.69–12.57 | 9.52 (0.46) | 7.87–13.24 |
SNR | 10.05 (0.75) | 7.15–15.09 | 8.52 (0.61) | 5.36–10.76 | 8.05 (0.49) | 6.04–10.06 |
PRESS | ||||||
CRLB (%) | 7.18 (0.263) | 6–9 | 7.62 (0.21) | 7–9 | 7.42 (0.23) | 6–9 |
FWHM (Hz) | 6.39 (0.53) | 4.22–9.71 | 5.94 (0.36) | 4.22–8.56 | 5.88 (0.50) | 4.22–10.99 |
SNR | 40 (2.59) | 30–58 | 40.46 (1.54) | 34–50 | 35.42 (1.68) | 28–49 |
S.E. standard error, FWHM full width at half maximum, SNR signal-to-noise ratio, CRLB Cramér-Rao Lower Bound.